These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 25740662)

  • 1. Deep brain stimulation for Alzheimer disease: a decision and cost-effectiveness analysis.
    Mirsaeedi-Farahani K; Halpern CH; Baltuch GH; Wolk DA; Stein SC
    J Neurol; 2015 May; 262(5):1191-7. PubMed ID: 25740662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis.
    Stephen JH; Halpern CH; Barrios CJ; Balmuri U; Pisapia JM; Wolf JA; Kampman KM; Baltuch GH; Caplan AL; Stein SC
    Addiction; 2012 Mar; 107(3):624-34. PubMed ID: 21919988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Deep Brain Stimulation in Patients with Parkinson's Disease in Japan.
    Kawamoto Y; Mouri M; Taira T; Iseki H; Masamune K
    World Neurosurg; 2016 May; 89():628-635.e1. PubMed ID: 26704203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Deep Brain Stimulation for Advanced Parkinson's Disease in the United States.
    Pietzsch JB; Garner AM; Marks WJ
    Neuromodulation; 2016 Oct; 19(7):689-697. PubMed ID: 27491661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease.
    Dams J; Siebert U; Bornschein B; Volkmann J; Deuschl G; Oertel WH; Dodel R; Reese JP
    Mov Disord; 2013 Jun; 28(6):763-71. PubMed ID: 23576266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep Brain Stimulation Targeting the Fornix for Mild Alzheimer Dementia (the ADvance Trial): A Two Year Follow-up Including Results of Delayed Activation.
    Leoutsakos JS; Yan H; Anderson WS; Asaad WF; Baltuch G; Burke A; Chakravarty MM; Drake KE; Foote KD; Fosdick L; Giacobbe P; Mari Z; McAndrews MP; Munro CA; Oh ES; Okun MS; Pendergrass JC; Ponce FA; Rosenberg PB; Sabbagh MN; Salloway S; Tang-Wai DF; Targum SD; Wolk D; Lozano AM; Smith GS; Lyketsos CG
    J Alzheimers Dis; 2018; 64(2):597-606. PubMed ID: 29914028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of deep brain stimulation versus treatment as usual for obsessive-compulsive disorder.
    Ooms P; Blankers M; Figee M; Bergfeld IO; van den Munckhof P; Schuurman PR; Denys D
    Brain Stimul; 2017; 10(4):836-842. PubMed ID: 28457837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis.
    Tomaszewski KJ; Holloway RG
    Neurology; 2001 Aug; 57(4):663-71. PubMed ID: 11524476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer's disease.
    Lee SA; Sposato LA; Hachinski V; Cipriano LE
    Alzheimers Res Ther; 2017 Mar; 9(1):18. PubMed ID: 28302164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of subthalmic nucleus deep brain stimulation for the treatment of advanced Parkinson disease in Hong Kong: a prospective study.
    Zhu XL; Chan DT; Lau CK; Poon WS; Mok VC; Chan AY; Wong LK; Yeung JH; Leung MC; Tang VY; Wong RK; Yeung C
    World Neurosurg; 2014 Dec; 82(6):987-93. PubMed ID: 25175275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada.
    Gagnon M; Rive B; Hux M; Guilhaume C
    Can J Psychiatry; 2007 Aug; 52(8):519-26. PubMed ID: 17955915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
    Walter E; Odin P
    J Med Econ; 2015 Feb; 18(2):155-65. PubMed ID: 25348011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulate or degenerate: deep brain stimulation of the nucleus basalis Meynert in Alzheimer dementia.
    Hardenacke K; Kuhn J; Lenartz D; Maarouf M; Mai JK; Bartsch C; Freund HJ; Sturm V
    World Neurosurg; 2013; 80(3-4):S27.e35-43. PubMed ID: 23246738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness and threshold analysis of deep brain stimulation vs. treatment-as-usual for treatment-resistant depression.
    Kabotyanski KE; Najera RA; Banks GP; Sharma H; Provenza NR; Hayden BY; Mathew SJ; Sheth SA
    Transl Psychiatry; 2024 Jun; 14(1):243. PubMed ID: 38849334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective.
    Hornberger J; Michalopoulos S; Dai M; Andrade P; Dilla T; Happich M
    J Ment Health Policy Econ; 2015 Jun; 18(2):63-73. PubMed ID: 26231002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease.
    Valldeoriola F; Morsi O; Tolosa E; Rumià J; Martí MJ; Martínez-Martín P
    Mov Disord; 2007 Nov; 22(15):2183-91. PubMed ID: 17724747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of deep-brain stimulation for Tourette's syndrome: an initial exploration.
    Dang TTH; Rowell D; Liddle J; Coyne T; Silburn P; Connelly LB
    J Neurol; 2019 Dec; 266(12):2997-3008. PubMed ID: 31485722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of deep brain stimulation for patients with treatment-resistant obsessive-compulsive disorder.
    Moon W; Kim SN; Park S; Paek SH; Kwon JS
    Medicine (Baltimore); 2017 Jul; 96(27):e7397. PubMed ID: 28682894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep brain stimulation for the treatment of Alzheimer disease and dementias.
    Laxton AW; Lozano AM
    World Neurosurg; 2013; 80(3-4):S28.e1-8. PubMed ID: 22722036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
    Fuh JL; Wang SJ
    Int J Geriatr Psychiatry; 2008 Jan; 23(1):73-8. PubMed ID: 17520661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.